IVD Antibodies
IVD Antibodies

IVD Antibodies Comprehensive Study by Type (Cardiac Markers, Tumor Markers, Kidney Injury Markers, Infection and Inflammation Antibodies), Application (Immunology, Cancer, Cardiovascular Diseases), End User (Hospitals, Diagnostic Laboratories, Homecare settings, Others) Players and Region - Global Market Outlook to 2027

IVD Antibodies Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

May 2022 Edition 206 Pages 64 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is IVD Antibodies?
IVD are exams used to observe and in prognosis of disease, infections or different scientific conditions, along with a willpower of the nation of health, in order to cure, mitigate, treat, or forestall disorder or its sequelae. They’re meant for use in the collection, preparation, and examination of specimens taken from the human body. Common makes use of for in vitro diagnostics along with however no longer restricted to ailment screening, infections detecting, therapeutic monitoring, making sure blood is protected to be used in transfusions, and recognizing of allergic reactions and the size of hormones and different organic markers in physique specimen. Antibodies have come to be a crucial issue of many diagnostic assays. Creative Biolabs develops and licenses antibodies for use in In Vitro Diagnostic (IVD) assays as a certified IVD supplier. With built-in antibody improvement and engineering techniques, provide a complete IVD antibody and immunodiagnostic package improvement platform that presents both character provider modules and an utterly complete service.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledAbcam (United Kingdom), Thermo Fisher Scientific (United States), Rockland Immunochemicals (United States), GenScript (United States), Bio-Rad Laboratories (United States), SDIX (United States), MEDICAL & BIOLOGICAL LABORATORIES (Japan), HyTest (Finland) and Abbott (United States)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global IVD Antibodies market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abcam (United Kingdom), Thermo Fisher Scientific (United States), Rockland Immunochemicals (United States), GenScript (United States), Bio-Rad Laboratories (United States), SDIX (United States), MEDICAL & BIOLOGICAL LABORATORIES (Japan), HyTest (Finland) and Abbott (United States) are some of the key players that are part of study coverage.

The market study is broken down by Type (Cardiac Markers, Tumor Markers, Kidney Injury Markers and Infection and Inflammation Antibodies), by Application (Immunology, Cancer and Cardiovascular Diseases) and major geographies with country level break-up.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global IVD Antibodies market by Type, Application and Region.

On the basis of geography, the market of IVD Antibodies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospitals will boost the IVD Antibodies market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
In September 2021, Thermo Fisher Scientific’s medical sequencing commercial enterprise and AstraZeneca entered into a settlement to co-develop NGS-based associate diagnostics (CDx) to assist AstraZeneca’s increasing portfolio of focused therapies.
In 2020, abbot launched its more than one molecular take a look at on its alinity m machine to realize COVID-19, flu A, flu B, and respiratory Synctial virus pursuant to a CE Mark.


Market Trend
  • Automation of Clinical Laboratory Techniques
  • Microfluids Based Poc and Alb-On-Chip Diagnostic Devices for Laboratory Testing
  • Increasing Number of Reagents Rental Agreements

Market Drivers
  • Growing Incidence of Chronic Diseases Such As HIV, Hepatitis, Cancer, Cardiovascular Diseases, Etc.

Opportunities
  • Development of Disease-Specific Biomarkers and Tests

Restraints
  • Low Product Penetration
  • Higher Cost Of the IVD Antibodies

Challenges
  • Changing Regulatory Landscape in the EU


About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Abcam (United Kingdom), Thermo Fisher Scientific (United States), Rockland Immunochemicals (United States), GenScript (United States), Bio-Rad Laboratories (United States), SDIX (United States), MEDICAL & BIOLOGICAL LABORATORIES (Japan), HyTest (Finland) and Abbott (United States) etc.

2. Can we have customized study for IVD Antibodies Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Report Objectives / Segmentation Covered
By Type
  • Cardiac Markers
  • Tumor Markers
  • Kidney Injury Markers
  • Infection and Inflammation Antibodies
By Application
  • Immunology
  • Cancer
  • Cardiovascular Diseases
By End User
  • Hospitals
  • Diagnostic Laboratories
  • Homecare settings
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Incidence of Chronic Diseases Such As HIV, Hepatitis, Cancer, Cardiovascular Diseases, Etc.
    • 3.3. Market Challenges
      • 3.3.1. Changing Regulatory Landscape in the EU
    • 3.4. Market Trends
      • 3.4.1. Automation of Clinical Laboratory Techniques
      • 3.4.2. Microfluids Based Poc and Alb-On-Chip Diagnostic Devices for Laboratory Testing
      • 3.4.3. Increasing Number of Reagents Rental Agreements
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global IVD Antibodies, by Type, Application, End User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global IVD Antibodies (Value)
      • 5.2.1. Global IVD Antibodies by: Type (Value)
        • 5.2.1.1. Cardiac Markers
        • 5.2.1.2. Tumor Markers
        • 5.2.1.3. Kidney Injury Markers
        • 5.2.1.4. Infection and Inflammation Antibodies
      • 5.2.2. Global IVD Antibodies by: Application (Value)
        • 5.2.2.1. Immunology
        • 5.2.2.2. Cancer
        • 5.2.2.3. Cardiovascular Diseases
      • 5.2.3. Global IVD Antibodies by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Diagnostic Laboratories
        • 5.2.3.3. Homecare settings
        • 5.2.3.4. Others
      • 5.2.4. Global IVD Antibodies Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. IVD Antibodies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abcam (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Rockland Immunochemicals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GenScript (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bio-Rad Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. SDIX (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MEDICAL & BIOLOGICAL LABORATORIES (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. HyTest (Finland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global IVD Antibodies Sale, by Type, Application, End User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global IVD Antibodies (Value)
      • 7.2.1. Global IVD Antibodies by: Type (Value)
        • 7.2.1.1. Cardiac Markers
        • 7.2.1.2. Tumor Markers
        • 7.2.1.3. Kidney Injury Markers
        • 7.2.1.4. Infection and Inflammation Antibodies
      • 7.2.2. Global IVD Antibodies by: Application (Value)
        • 7.2.2.1. Immunology
        • 7.2.2.2. Cancer
        • 7.2.2.3. Cardiovascular Diseases
      • 7.2.3. Global IVD Antibodies by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Diagnostic Laboratories
        • 7.2.3.3. Homecare settings
        • 7.2.3.4. Others
      • 7.2.4. Global IVD Antibodies Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. IVD Antibodies: by Type(USD Million)
  • Table 2. IVD Antibodies Cardiac Markers , by Region USD Million (2016-2021)
  • Table 3. IVD Antibodies Tumor Markers , by Region USD Million (2016-2021)
  • Table 4. IVD Antibodies Kidney Injury Markers , by Region USD Million (2016-2021)
  • Table 5. IVD Antibodies Infection and Inflammation Antibodies , by Region USD Million (2016-2021)
  • Table 6. IVD Antibodies: by Application(USD Million)
  • Table 7. IVD Antibodies Immunology , by Region USD Million (2016-2021)
  • Table 8. IVD Antibodies Cancer , by Region USD Million (2016-2021)
  • Table 9. IVD Antibodies Cardiovascular Diseases , by Region USD Million (2016-2021)
  • Table 10. IVD Antibodies: by End User(USD Million)
  • Table 11. IVD Antibodies Hospitals , by Region USD Million (2016-2021)
  • Table 12. IVD Antibodies Diagnostic Laboratories , by Region USD Million (2016-2021)
  • Table 13. IVD Antibodies Homecare settings , by Region USD Million (2016-2021)
  • Table 14. IVD Antibodies Others , by Region USD Million (2016-2021)
  • Table 15. South America IVD Antibodies, by Country USD Million (2016-2021)
  • Table 16. South America IVD Antibodies, by Type USD Million (2016-2021)
  • Table 17. South America IVD Antibodies, by Application USD Million (2016-2021)
  • Table 18. South America IVD Antibodies, by End User USD Million (2016-2021)
  • Table 19. Brazil IVD Antibodies, by Type USD Million (2016-2021)
  • Table 20. Brazil IVD Antibodies, by Application USD Million (2016-2021)
  • Table 21. Brazil IVD Antibodies, by End User USD Million (2016-2021)
  • Table 22. Argentina IVD Antibodies, by Type USD Million (2016-2021)
  • Table 23. Argentina IVD Antibodies, by Application USD Million (2016-2021)
  • Table 24. Argentina IVD Antibodies, by End User USD Million (2016-2021)
  • Table 25. Rest of South America IVD Antibodies, by Type USD Million (2016-2021)
  • Table 26. Rest of South America IVD Antibodies, by Application USD Million (2016-2021)
  • Table 27. Rest of South America IVD Antibodies, by End User USD Million (2016-2021)
  • Table 28. Asia Pacific IVD Antibodies, by Country USD Million (2016-2021)
  • Table 29. Asia Pacific IVD Antibodies, by Type USD Million (2016-2021)
  • Table 30. Asia Pacific IVD Antibodies, by Application USD Million (2016-2021)
  • Table 31. Asia Pacific IVD Antibodies, by End User USD Million (2016-2021)
  • Table 32. China IVD Antibodies, by Type USD Million (2016-2021)
  • Table 33. China IVD Antibodies, by Application USD Million (2016-2021)
  • Table 34. China IVD Antibodies, by End User USD Million (2016-2021)
  • Table 35. Japan IVD Antibodies, by Type USD Million (2016-2021)
  • Table 36. Japan IVD Antibodies, by Application USD Million (2016-2021)
  • Table 37. Japan IVD Antibodies, by End User USD Million (2016-2021)
  • Table 38. India IVD Antibodies, by Type USD Million (2016-2021)
  • Table 39. India IVD Antibodies, by Application USD Million (2016-2021)
  • Table 40. India IVD Antibodies, by End User USD Million (2016-2021)
  • Table 41. South Korea IVD Antibodies, by Type USD Million (2016-2021)
  • Table 42. South Korea IVD Antibodies, by Application USD Million (2016-2021)
  • Table 43. South Korea IVD Antibodies, by End User USD Million (2016-2021)
  • Table 44. Taiwan IVD Antibodies, by Type USD Million (2016-2021)
  • Table 45. Taiwan IVD Antibodies, by Application USD Million (2016-2021)
  • Table 46. Taiwan IVD Antibodies, by End User USD Million (2016-2021)
  • Table 47. Australia IVD Antibodies, by Type USD Million (2016-2021)
  • Table 48. Australia IVD Antibodies, by Application USD Million (2016-2021)
  • Table 49. Australia IVD Antibodies, by End User USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific IVD Antibodies, by Type USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific IVD Antibodies, by Application USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific IVD Antibodies, by End User USD Million (2016-2021)
  • Table 53. Europe IVD Antibodies, by Country USD Million (2016-2021)
  • Table 54. Europe IVD Antibodies, by Type USD Million (2016-2021)
  • Table 55. Europe IVD Antibodies, by Application USD Million (2016-2021)
  • Table 56. Europe IVD Antibodies, by End User USD Million (2016-2021)
  • Table 57. Germany IVD Antibodies, by Type USD Million (2016-2021)
  • Table 58. Germany IVD Antibodies, by Application USD Million (2016-2021)
  • Table 59. Germany IVD Antibodies, by End User USD Million (2016-2021)
  • Table 60. France IVD Antibodies, by Type USD Million (2016-2021)
  • Table 61. France IVD Antibodies, by Application USD Million (2016-2021)
  • Table 62. France IVD Antibodies, by End User USD Million (2016-2021)
  • Table 63. Italy IVD Antibodies, by Type USD Million (2016-2021)
  • Table 64. Italy IVD Antibodies, by Application USD Million (2016-2021)
  • Table 65. Italy IVD Antibodies, by End User USD Million (2016-2021)
  • Table 66. United Kingdom IVD Antibodies, by Type USD Million (2016-2021)
  • Table 67. United Kingdom IVD Antibodies, by Application USD Million (2016-2021)
  • Table 68. United Kingdom IVD Antibodies, by End User USD Million (2016-2021)
  • Table 69. Netherlands IVD Antibodies, by Type USD Million (2016-2021)
  • Table 70. Netherlands IVD Antibodies, by Application USD Million (2016-2021)
  • Table 71. Netherlands IVD Antibodies, by End User USD Million (2016-2021)
  • Table 72. Rest of Europe IVD Antibodies, by Type USD Million (2016-2021)
  • Table 73. Rest of Europe IVD Antibodies, by Application USD Million (2016-2021)
  • Table 74. Rest of Europe IVD Antibodies, by End User USD Million (2016-2021)
  • Table 75. MEA IVD Antibodies, by Country USD Million (2016-2021)
  • Table 76. MEA IVD Antibodies, by Type USD Million (2016-2021)
  • Table 77. MEA IVD Antibodies, by Application USD Million (2016-2021)
  • Table 78. MEA IVD Antibodies, by End User USD Million (2016-2021)
  • Table 79. Middle East IVD Antibodies, by Type USD Million (2016-2021)
  • Table 80. Middle East IVD Antibodies, by Application USD Million (2016-2021)
  • Table 81. Middle East IVD Antibodies, by End User USD Million (2016-2021)
  • Table 82. Africa IVD Antibodies, by Type USD Million (2016-2021)
  • Table 83. Africa IVD Antibodies, by Application USD Million (2016-2021)
  • Table 84. Africa IVD Antibodies, by End User USD Million (2016-2021)
  • Table 85. North America IVD Antibodies, by Country USD Million (2016-2021)
  • Table 86. North America IVD Antibodies, by Type USD Million (2016-2021)
  • Table 87. North America IVD Antibodies, by Application USD Million (2016-2021)
  • Table 88. North America IVD Antibodies, by End User USD Million (2016-2021)
  • Table 89. United States IVD Antibodies, by Type USD Million (2016-2021)
  • Table 90. United States IVD Antibodies, by Application USD Million (2016-2021)
  • Table 91. United States IVD Antibodies, by End User USD Million (2016-2021)
  • Table 92. Canada IVD Antibodies, by Type USD Million (2016-2021)
  • Table 93. Canada IVD Antibodies, by Application USD Million (2016-2021)
  • Table 94. Canada IVD Antibodies, by End User USD Million (2016-2021)
  • Table 95. Mexico IVD Antibodies, by Type USD Million (2016-2021)
  • Table 96. Mexico IVD Antibodies, by Application USD Million (2016-2021)
  • Table 97. Mexico IVD Antibodies, by End User USD Million (2016-2021)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. IVD Antibodies: by Type(USD Million)
  • Table 108. IVD Antibodies Cardiac Markers , by Region USD Million (2022-2027)
  • Table 109. IVD Antibodies Tumor Markers , by Region USD Million (2022-2027)
  • Table 110. IVD Antibodies Kidney Injury Markers , by Region USD Million (2022-2027)
  • Table 111. IVD Antibodies Infection and Inflammation Antibodies , by Region USD Million (2022-2027)
  • Table 112. IVD Antibodies: by Application(USD Million)
  • Table 113. IVD Antibodies Immunology , by Region USD Million (2022-2027)
  • Table 114. IVD Antibodies Cancer , by Region USD Million (2022-2027)
  • Table 115. IVD Antibodies Cardiovascular Diseases , by Region USD Million (2022-2027)
  • Table 116. IVD Antibodies: by End User(USD Million)
  • Table 117. IVD Antibodies Hospitals , by Region USD Million (2022-2027)
  • Table 118. IVD Antibodies Diagnostic Laboratories , by Region USD Million (2022-2027)
  • Table 119. IVD Antibodies Homecare settings , by Region USD Million (2022-2027)
  • Table 120. IVD Antibodies Others , by Region USD Million (2022-2027)
  • Table 121. South America IVD Antibodies, by Country USD Million (2022-2027)
  • Table 122. South America IVD Antibodies, by Type USD Million (2022-2027)
  • Table 123. South America IVD Antibodies, by Application USD Million (2022-2027)
  • Table 124. South America IVD Antibodies, by End User USD Million (2022-2027)
  • Table 125. Brazil IVD Antibodies, by Type USD Million (2022-2027)
  • Table 126. Brazil IVD Antibodies, by Application USD Million (2022-2027)
  • Table 127. Brazil IVD Antibodies, by End User USD Million (2022-2027)
  • Table 128. Argentina IVD Antibodies, by Type USD Million (2022-2027)
  • Table 129. Argentina IVD Antibodies, by Application USD Million (2022-2027)
  • Table 130. Argentina IVD Antibodies, by End User USD Million (2022-2027)
  • Table 131. Rest of South America IVD Antibodies, by Type USD Million (2022-2027)
  • Table 132. Rest of South America IVD Antibodies, by Application USD Million (2022-2027)
  • Table 133. Rest of South America IVD Antibodies, by End User USD Million (2022-2027)
  • Table 134. Asia Pacific IVD Antibodies, by Country USD Million (2022-2027)
  • Table 135. Asia Pacific IVD Antibodies, by Type USD Million (2022-2027)
  • Table 136. Asia Pacific IVD Antibodies, by Application USD Million (2022-2027)
  • Table 137. Asia Pacific IVD Antibodies, by End User USD Million (2022-2027)
  • Table 138. China IVD Antibodies, by Type USD Million (2022-2027)
  • Table 139. China IVD Antibodies, by Application USD Million (2022-2027)
  • Table 140. China IVD Antibodies, by End User USD Million (2022-2027)
  • Table 141. Japan IVD Antibodies, by Type USD Million (2022-2027)
  • Table 142. Japan IVD Antibodies, by Application USD Million (2022-2027)
  • Table 143. Japan IVD Antibodies, by End User USD Million (2022-2027)
  • Table 144. India IVD Antibodies, by Type USD Million (2022-2027)
  • Table 145. India IVD Antibodies, by Application USD Million (2022-2027)
  • Table 146. India IVD Antibodies, by End User USD Million (2022-2027)
  • Table 147. South Korea IVD Antibodies, by Type USD Million (2022-2027)
  • Table 148. South Korea IVD Antibodies, by Application USD Million (2022-2027)
  • Table 149. South Korea IVD Antibodies, by End User USD Million (2022-2027)
  • Table 150. Taiwan IVD Antibodies, by Type USD Million (2022-2027)
  • Table 151. Taiwan IVD Antibodies, by Application USD Million (2022-2027)
  • Table 152. Taiwan IVD Antibodies, by End User USD Million (2022-2027)
  • Table 153. Australia IVD Antibodies, by Type USD Million (2022-2027)
  • Table 154. Australia IVD Antibodies, by Application USD Million (2022-2027)
  • Table 155. Australia IVD Antibodies, by End User USD Million (2022-2027)
  • Table 156. Rest of Asia-Pacific IVD Antibodies, by Type USD Million (2022-2027)
  • Table 157. Rest of Asia-Pacific IVD Antibodies, by Application USD Million (2022-2027)
  • Table 158. Rest of Asia-Pacific IVD Antibodies, by End User USD Million (2022-2027)
  • Table 159. Europe IVD Antibodies, by Country USD Million (2022-2027)
  • Table 160. Europe IVD Antibodies, by Type USD Million (2022-2027)
  • Table 161. Europe IVD Antibodies, by Application USD Million (2022-2027)
  • Table 162. Europe IVD Antibodies, by End User USD Million (2022-2027)
  • Table 163. Germany IVD Antibodies, by Type USD Million (2022-2027)
  • Table 164. Germany IVD Antibodies, by Application USD Million (2022-2027)
  • Table 165. Germany IVD Antibodies, by End User USD Million (2022-2027)
  • Table 166. France IVD Antibodies, by Type USD Million (2022-2027)
  • Table 167. France IVD Antibodies, by Application USD Million (2022-2027)
  • Table 168. France IVD Antibodies, by End User USD Million (2022-2027)
  • Table 169. Italy IVD Antibodies, by Type USD Million (2022-2027)
  • Table 170. Italy IVD Antibodies, by Application USD Million (2022-2027)
  • Table 171. Italy IVD Antibodies, by End User USD Million (2022-2027)
  • Table 172. United Kingdom IVD Antibodies, by Type USD Million (2022-2027)
  • Table 173. United Kingdom IVD Antibodies, by Application USD Million (2022-2027)
  • Table 174. United Kingdom IVD Antibodies, by End User USD Million (2022-2027)
  • Table 175. Netherlands IVD Antibodies, by Type USD Million (2022-2027)
  • Table 176. Netherlands IVD Antibodies, by Application USD Million (2022-2027)
  • Table 177. Netherlands IVD Antibodies, by End User USD Million (2022-2027)
  • Table 178. Rest of Europe IVD Antibodies, by Type USD Million (2022-2027)
  • Table 179. Rest of Europe IVD Antibodies, by Application USD Million (2022-2027)
  • Table 180. Rest of Europe IVD Antibodies, by End User USD Million (2022-2027)
  • Table 181. MEA IVD Antibodies, by Country USD Million (2022-2027)
  • Table 182. MEA IVD Antibodies, by Type USD Million (2022-2027)
  • Table 183. MEA IVD Antibodies, by Application USD Million (2022-2027)
  • Table 184. MEA IVD Antibodies, by End User USD Million (2022-2027)
  • Table 185. Middle East IVD Antibodies, by Type USD Million (2022-2027)
  • Table 186. Middle East IVD Antibodies, by Application USD Million (2022-2027)
  • Table 187. Middle East IVD Antibodies, by End User USD Million (2022-2027)
  • Table 188. Africa IVD Antibodies, by Type USD Million (2022-2027)
  • Table 189. Africa IVD Antibodies, by Application USD Million (2022-2027)
  • Table 190. Africa IVD Antibodies, by End User USD Million (2022-2027)
  • Table 191. North America IVD Antibodies, by Country USD Million (2022-2027)
  • Table 192. North America IVD Antibodies, by Type USD Million (2022-2027)
  • Table 193. North America IVD Antibodies, by Application USD Million (2022-2027)
  • Table 194. North America IVD Antibodies, by End User USD Million (2022-2027)
  • Table 195. United States IVD Antibodies, by Type USD Million (2022-2027)
  • Table 196. United States IVD Antibodies, by Application USD Million (2022-2027)
  • Table 197. United States IVD Antibodies, by End User USD Million (2022-2027)
  • Table 198. Canada IVD Antibodies, by Type USD Million (2022-2027)
  • Table 199. Canada IVD Antibodies, by Application USD Million (2022-2027)
  • Table 200. Canada IVD Antibodies, by End User USD Million (2022-2027)
  • Table 201. Mexico IVD Antibodies, by Type USD Million (2022-2027)
  • Table 202. Mexico IVD Antibodies, by Application USD Million (2022-2027)
  • Table 203. Mexico IVD Antibodies, by End User USD Million (2022-2027)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global IVD Antibodies: by Type USD Million (2016-2021)
  • Figure 5. Global IVD Antibodies: by Application USD Million (2016-2021)
  • Figure 6. Global IVD Antibodies: by End User USD Million (2016-2021)
  • Figure 7. South America IVD Antibodies Share (%), by Country
  • Figure 8. Asia Pacific IVD Antibodies Share (%), by Country
  • Figure 9. Europe IVD Antibodies Share (%), by Country
  • Figure 10. MEA IVD Antibodies Share (%), by Country
  • Figure 11. North America IVD Antibodies Share (%), by Country
  • Figure 12. Global IVD Antibodies share by Players 2021 (%)
  • Figure 13. Global IVD Antibodies share by Players (Top 3) 2021(%)
  • Figure 14. Global IVD Antibodies share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abcam (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. Abcam (United Kingdom) Revenue: by Geography 2021
  • Figure 18. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 19. Thermo Fisher Scientific (United States) Revenue: by Geography 2021
  • Figure 20. Rockland Immunochemicals (United States) Revenue, Net Income and Gross profit
  • Figure 21. Rockland Immunochemicals (United States) Revenue: by Geography 2021
  • Figure 22. GenScript (United States) Revenue, Net Income and Gross profit
  • Figure 23. GenScript (United States) Revenue: by Geography 2021
  • Figure 24. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 25. Bio-Rad Laboratories (United States) Revenue: by Geography 2021
  • Figure 26. SDIX (United States) Revenue, Net Income and Gross profit
  • Figure 27. SDIX (United States) Revenue: by Geography 2021
  • Figure 28. MEDICAL & BIOLOGICAL LABORATORIES (Japan) Revenue, Net Income and Gross profit
  • Figure 29. MEDICAL & BIOLOGICAL LABORATORIES (Japan) Revenue: by Geography 2021
  • Figure 30. HyTest (Finland) Revenue, Net Income and Gross profit
  • Figure 31. HyTest (Finland) Revenue: by Geography 2021
  • Figure 32. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 33. Abbott (United States) Revenue: by Geography 2021
  • Figure 34. Global IVD Antibodies: by Type USD Million (2022-2027)
  • Figure 35. Global IVD Antibodies: by Application USD Million (2022-2027)
  • Figure 36. Global IVD Antibodies: by End User USD Million (2022-2027)
  • Figure 37. South America IVD Antibodies Share (%), by Country
  • Figure 38. Asia Pacific IVD Antibodies Share (%), by Country
  • Figure 39. Europe IVD Antibodies Share (%), by Country
  • Figure 40. MEA IVD Antibodies Share (%), by Country
  • Figure 41. North America IVD Antibodies Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Abcam (United Kingdom)
  • Thermo Fisher Scientific (United States)
  • Rockland Immunochemicals (United States)
  • GenScript (United States)
  • Bio-Rad Laboratories (United States)
  • SDIX (United States)
  • MEDICAL & BIOLOGICAL LABORATORIES (Japan)
  • HyTest (Finland)
  • Abbott (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation